Sachdeva JS, Chu SM, Bargman JM
Clinical experience with intraperitoneal EPO in adult patients
on peritoneal dialysis
17th Annual CAPD Conference
Perit Dial Int Suppl 1
(Feb) 17:S99 1997
EPO is usually given subcutaneously in PD patients, especially with new
evidence (see Sands in Feb, 1997 JASN) that once-weekly subQ dosing appears
to be quite effective. Nevertheless, some centers continue to experiment
with IP dosing. In this paper Sachdeva et al gave IP EPO presumably on a
2x/week schedule to 10 iron-replete PD patients. The mean dose was 140
U/kg/week. The Hgb increased from 8.2 to 11.2 g/dl after a median of 6
months of therapy. One patient failed to respond and did have a better
response to subQ EPO. Ten episodes of peritonitis occurred in 239 patient-
months of follow-up, which appears to be a reasonable rate.
Comment: The conclusion is that IP EPO can be a safe and effective
alternative EPO route for patients unwilling to take the subQ injections.
However, I think a once-weekly dosing schedule would be accepted by most
patients. See also
Taylor et al.
(John T. Daugirdas, M.D., University of Illinois at Chicago)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
17th Annual CAPD Conference
CRF by problem area :
Anemia/Erythropoietin/Iron